Helmy Eltoukhy
Co-Founder, Co-CEO & ChairmanDr. Helmy Eltoukhy is Director of Stanford Health Care from 2026. He is Director of Ellipsis Health, Inc. from October 2025. Dr. Helmy Eltoukhy, Ph.D., is Director of Paradromics, Inc. He is Partner of Green Sands Equity Incorporated. He is Equity Partner and Advisor of Transform VC. Dr. Eltoukhy has been the Chairman of the Board of Directors of Guardant Health, Inc. since August 05, 2021. He has been the Co-Chief Executive Officer at Guardant Health, Inc. since August 05, 2021. He is the Co-Founder of Guardant Health Inc. and had been its Chief Executive Officer since January 2013 until August 05, 2021. He has been a Director of Guardant Health, Inc. since January 2013. Dr. Eltoukhy is a serial entrepreneur and pioneer in the biotech industry. He joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome, Inc. to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As founding Chief Executive Officer, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. Dr. Eltoukhy held various positions at Illumina, Incorporated from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007, he co-founded Avantome Incorporated. He developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. Dr. Helmy Eltoukhy received his PhD, MS and BS degrees in electrical engineering from Stanford University.
Positions
- Company NameGuardant Health, Inc.Stock CodeGHPositionCo-Founder, Co-CEO & ChairmanColleagues
